Phase 3 Study of the Safety and Efficacy of OmegaD Softgels in the Treatment of Dry Eye Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

322

Participants

Timeline

Start Date

November 18, 2019

Primary Completion Date

February 28, 2021

Study Completion Date

February 28, 2021

Conditions
Dry Eye
Interventions
DRUG

Omega 3 fatty acid

Omega 3 fatty acid Softgels

DRUG

Placebos

Mineral oil Softgels

Trial Locations (14)

21078

Seidenberg Protzko Eye Associates, Havre de Grace

30260

Clayton Eye Clinical Research, Morrow

33773

Shettle Eye Research inc, Largo

37205

Advancing Vision Research, Nashville

38119

Total Eye Care, Memphis

44115

Abrams Eye Center, Cleveland

63131

Ophthalmology Associates, St Louis

64133

Silverstein Eye Centers, Kansas City

66204

Heart of America Eye Care, Shawnee Mission

66762

Kannarr Eye Care, Pittsburg

78229

R and R Eye Research, San Antonio

92663

Eye Research Foundation, Newport Beach

92683

Michael K Tran Inc, Westminster

02888

West Bay Eye Associates, Warwick

All Listed Sponsors
lead

OmegaD LLC

INDUSTRY

NCT04181593 - Phase 3 Study of the Safety and Efficacy of OmegaD Softgels in the Treatment of Dry Eye Disease | Biotech Hunter | Biotech Hunter